U.S. SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549

            Form 10-QSB - Quarterly or Transitional Report
            (Added by 34-30968, eff. 8/13/93, as amended)

(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2001.

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
    EXCHANGE ACT OF 1934

For the transition period from _________________ to _____________


Commission file number 0-10035

                           LESCARDEN, INC.
--------------------------------------------------------------------
 (Exact name of small business issuer as specified in its charter)

      NEW YORK                                   13-2538207
-------------------------------               -------------------
(State or other jurisdiction of              (I.R.S. Employer
 incorporation or organization)               Identification No.)

420 LEXINGTON AVENUE, NEW YORK SUITE 212            10170
----------------------------------------      -------------------
(Address of principle executive offices)          (Zip Code)

Issuer's telephone number (212) 687-1050
                          --------------

________________________________________________________________.
(Former name, former address and former fiscal year, if changed
                          since last report)

     Check whether the issuer (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.

Yes [X]   No [ ]

State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.


            Class                       Outstanding at November 30,2001
----------------------------            -------------------------------
Common Stock $.001 par value                       22,635,356

<PAGE>


                            LESCARDEN INC.
                            --------------
<TABLE>

                       CONDENSED BALANCE SHEET
                       -----------------------
<CAPTION>

                                ASSETS
                                ------

                                                               November 30, 2001      May 31, 2001
                                                                  (UNAUDITED)           (AUDITED)
                                                               -----------------      ------------
<S>                                                               <C>                 <C>
CURRENT ASSETS:
     Cash                                                         $        5,393      $     79,429
     Inventory                                                            79,452           102,812
                                                                  --------------      ------------
            TOTAL CURRENT ASSETS                                          84,845           182,241

Deferred Income Tax Asset, net of valuation allowance of
$2,563,000 and $2,502,000 at November 30, 2001 and
May 31, 2001 respectively                                                   -                 -
                                                                  --------------      ------------
     TOTAL ASSETS                                                 $       84,845      $    182,241
                                                                  --------------      ------------
                                                                  --------------      ------------

               LIABILITIES AND STOCKHOLDERS' DEFICIENCY

CURRENTS LIABILITIES:
    Accounts payable and accrued expenses                         $      112,230      $    119,580
    Advances from stockholders                                           505,000           445,000
    Unearned revenue                                                     105,000           105,000
                                                                  --------------      ------------
     TOTAL LIABILITIES                                                   722,230           669,580
                                                                  --------------      ------------
COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIENCY:
    Convertible Preferred Stock                                            1,840             1,840
      Common Stock                                                        22,635            22,435
      Additional Paid-In Capital                                      15,375,018        15,338,996
      Accumulated Deficit                                            (16,036,878)      (15,850,610)
                                                                  --------------      ------------
    STOCKHOLDERS' DEFICIENCY                                           (637,385)         (487,339)
                                                                  --------------      ------------

           TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY         $       84,845      $    182,241
                                                                  --------------      ------------
                                                                  --------------      ------------
See notes to financial statements
</TABLE>
<PAGE>
<TABLE>


                            LESCARDEN INC.
                            --------------

                  CONDENSED STATEMENTS OF OPERATIONS
                  ----------------------------------
<CAPTION>
								(UNAUDITED)				(UNAUDITED)
                                            For The Three Months         For the Six Months
                                            Ended November 30,           Ended November 30,
                                            --------------------         ------------------
<S>                                  <C>           <C>             <C>           <C>
                                             2001         2000            2001          2000
                                             ----         ----            ----          ----
Total Revenues                       $     10,727  $     8,633     $    30,963   $    17,921
                                     ------------  -----------     -----------   -----------
Costs and Expenses:
   Cost of Sales                            8,123        6,130          23,361        12,580
   Salaries - Officer                      19,820       38,452          54,882        77,680
   Salaries - Office                        3,415        4,670           8,130        11,141
   Professional Fees and Consulting        13,495       29,331          46,072        60,022
   Research and Development                  -          13,946             200        13,946
   Rent and Office Expenses                29,929       28,482          59,172        51,003
   Travel and Meetings                      1,748       14,169           3,162        19,500
   Taxes - Other                             -	            41             455           458
   Insurance                                  646        1,206             800         1,284
   Interest                                 8,141         -             16,222           600
   Other Administrative Expenses            1,826        6,637           4,775        13,411
                                     ------------  -----------     -----------   -----------
     Total Costs and Expenses              87,143      143,064         217,231       261,625
                                     ------------  -----------     -----------   -----------
     Net (Loss)                      $    (76,416) $  (134,431)    $  (186,268)  $  (243,704)
                                     ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------
     Net (Loss) Per Share            $       (.00) $      (.01)    $      (.01)  $      (.01)
                                     ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------

Weighted Average Number of
  Common Shares Outstanding            22,485,356   22,369,169      22,463,927    22,344,169
                                     ------------  -----------     -----------   -----------
                                     ------------  -----------     -----------   -----------


</TABLE>

See notes to financial statements
<PAGE>

                            LESCARDEN INC.
                            --------------

<TABLE>

                  CONDENSED STATEMENTS OF CASH FLOWS
                  ----------------------------------
<CAPTION>
                                                                            (UNAUDITED)
                                                                     For the Six Months Ended
                                                                             November 30,
                                                                     --------------------------
<S>                                                               <C>                <C>
                                                                            2001              2000
                                                                            ----              ----

CASH FLOWS (USED IN) OPERATIONS:
     Net (Loss)                                                   $     (186,268)    $    (243,704)
     Adjustments to reconcile net  loss to net
       cash used in operating activities:
       Imputed interest on advances from stockholders                     16,222              -
       Changes in operating assets and liabilities:
       Decrease in accounts receivable                                      -               71,532
       Decrease  in inventory                                             23,360            12,580
      (Decrease) in accounts payable and
        accrued expenses                                                  (7,350)          (40,407)
                                                                  --------------      ------------
     NET CASH FLOW (USED IN) OPERATIONS                                 (154,036)         (199,999)
                                                                  --------------      ------------
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
         Advances from stockholders                                       80,000           205,000
                                                                  --------------      ------------
 (Decrease) increase in cash                                             (74,036)            5,001

Cash- Beginning of period                                                 79,429            43,449
                                                                  --------------      ------------
Cash - End of period                                              $        5,393      $     48,450
                                                                  --------------      ------------
                                                                  --------------      ------------

SUPPLEMENTAL SCHEDULE OF NON-CASH
  FINANCING ACTIVITIES:
Conversion of advances received from
 related parties to common stock                                  $       20,000      $       -
                                                                  --------------      ------------
                                                                  --------------      ------------
Imputed interest                                                  $       16,222      $       -
                                                                  --------------      ------------
                                                                  --------------      ------------



</TABLE>
<PAGE>


See notes to financial statements

<PAGE>

                            LESCARDEN INC.
                            --------------
                                                       (UNAUDITED)
                                                        ---------
                    NOTES TO FINANCIAL STATEMENTS
                    -----------------------------
                           November 30, 2001
                           -----------------

Note 1 - General:

     The accompanying unaudited financial statements include all adjustments
which are, in the opinion of management, necessary for a fair statement of
the results for the interim periods. The statements have been prepared in
accordance with the requirements for Form 10-QSB and,therefore, do not
include all disclosures or financial details required by generally accepted
accounting principles. These condensed financial statements should be read in
conjunction with the financial statements and the notes thereto included in
the Company's Annual Report on Form 10-KSB for the year ended May 31, 2001.


     The results of operations for the interim periods are not necessarily
indicative of results to be expected for a full year's operations.

Note 2 - Inventory:

     Inventory at November 30, 2001 consists of the following:

               Finished Goods $      46,832
               Raw Materials         32,620
                              -------------
                              $      79,452
                              -------------
                              -------------
<PAGE>

                            LESCARDEN INC.
                            --------------

     Management's Discussion and Analysis of Financial Condition
                      and Results of Operations
     -----------------------------------------------------------
                           November 30, 2001
                           -----------------

Results of Operations
---------------------

Overview
--------

     Since its inception, the Company has primarily devoted its resources to
fund research, drug discovery and development.   In addition, the Company
licenses its technology for commercialization by other companies and in recent
fiscal years, the Company began sales of its proprietary bovine cartilage
material, BIO-CARTILAGE(R), as a food supplement, and direct sales to
consumers of a line of cosmetic products, which include the Company's
proprietary bovine cartilage material.  In the fiscal year May 31, 2000, the
Company made its initial two commercial shipments of its CATRIX(R) Wound
Dressing product pursuant to its agreement with ICN IBERICA, S.A., Spain.

     The Company has been unprofitable to date and may continue to incur
operating losses in the foreseeable future. The Company has sustained net
losses of approximately $16 million from inception to November 30, 2001.  The
Company has primarily financed its research and development activities through
a public offering of Common Stock, private placements of debt and equity
securities, and in recent years, revenues from licensing fees and product
sales.

Three months and six months ended November 30, 2001 compared to the three
months and six months ended November 30, 2000.
-------------------------------------------------------------------------


     The Company's revenues in the periods were primarily from the direct
sales to consumers of a line of cosmetic products, which include the Company's
proprietary bovine cartilage material. A significant portion of the Company's
revenues in six months ended November 30, 2001 were from the sale of
Bio-Cartilage(R)capsules to one customer.

     Total costs and expenses during the six months ended November 30, 2001
were 17% lower than those of the comparative period of the prior year
principally due to lower salaries, professional fees and consulting, research
and development, travel and meetings and other administrative expenses, which
were partially offset by higher cost of product sales and $16,222 of imputed
interest cost on advances from stockholders.

Liquidity and Capital Resources
-------------------------------

Overview
--------

     The Company has had losses from operations in each of the five years
ended May 31, 2001.  This trend may continue in the foreseeable future.
Working capital has been provided since the Company's inception primarily
from the sale of equity securities or from borrowings from its officers,
directors and shareholders and from outside investors, and in more recent
quarters, from revenues from licensing fees and product sales.

<PAGE>

Present Liquidity
-----------------

     The Company's present liquidity position is critical.  As of
November 30, 2001 the Company's total liabilities exceeded its total assets by
$ 637,385.  The Company will require additional product sales or funding
during, or shortly after the end of,  the current fiscal quarter ending
February 28, 2002, to sustain its operations.

     As a result of the history of losses incurred by the Company, the net
loss during the year ended May 31, 2001 of ($ 568,368), and the limited
amount of funds currently available to finance the Company's operations, the
report of the Company's independent Certified Public Accountants on the
Company's Financial Statements as of May 31, 2000 and 2001 contain an
explanatory paragraph indicating that the Company may be unable to continue
in existence.

     The Company's licensee of its CATRIX(R) product, in powder form only,
for topical wound healing purposes (see below) received its initial two
shipments from the Company in the year ended May 31, 2000.  In addition, the
Company continued to sell a line of cosmetic products and plans to continue
to implement plans to sell BIO-CARTILAGE(R) to the over-the-counter food
supplement market. If the Company's efforts to increase revenues are
successful, the Company may increase cash flow in order to allow the Company
to meet its obligations and sustain its operations.  The Company also plans
to try to obtain financing from additional advances from stockholders and
sales of unregistered shares of common stock.

     On March 16, 1999, the Company announced that it had entered into an
agreement with ICN IBERICA, S.A. ("ICNI", a wholly owned subsidiary of ICN
Pharmaceuticals, USA) of Barcelona, Spain whereby ICNI acquired the
semi-exclusive rights to distribute and market the Company's CATRIX(R)
WOUND CARE DRESSING in Spain for a period of ten years. Implementation of
this Agreement was contingent upon securing marketing approval for the
product by the Spanish Health Ministry.

     On September 13, 1999, the Company announced that its CATRIX(R) Wound
Dressing product was granted full marketing approval by the Spanish Health
Ministry of Madrid.  Under the prevailing regulations of the European Union
("EU"), of which Spain is a member, a drug/device approval in one member
country renders the product marketable in all member states.  Therefore,
CATRIX(R) Wound Dressing may now be sold throughout the 15 countries of
the EU.

     Since September 1999, the Company has fulfilled all of its obligations
under its agreement with ICNI, including the timely shipment of the product.
ICNI has commenced implementation of a complete marketing program in Spain,
and it also applied to the appropriate Spanish authorities for a government
sponsored reimbursement plan for patients covered under the national medical
care program.   The Spanish Health Ministry in the Spring of 2001 allowed
only a very low patient reimbursement rate.  As a result, ICNI is prosecuting
an appeal of this decision and the date for a resolution of the matter is
not determinate.

<PAGE>

     As a result of the low reimbursement rate allowed by the Spanish
government, ICNI has been unable to meet minimum sales levels as set forth
in the parties' agreement.  This has led the parties to agree to continue
their relationship absent an operational agreement until such time as ICNI's
appeal of its rate case has been decided by the Spanish Health Ministry.

     Spain's socialized medicine system covers about 80% of its population.
The other 20% are either privately insured or self insured.  Unless ICNI is
allowed an adequate reimbursement rate, its sales of CATRIX Wound Dressing
will be largely limited to 20% of the population.  At this time, no
representation can be made on the possible outcome of ICNI's rate appeal.

     The Company has no material commitments for capital expenditures at
November 30, 2001.


<PAGE>

                                      LESCARDEN INC.
                                      --------------

                     Part II - Other Information
                     ---------------------------

Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------

     (A)   Reports on Form 8-K: There were no reports on Form 8-K filed for
           the three months ended November 30, 2001.

                          INDEX TO EXHIBITS

<PAGE>

                              Signatures
                              ----------

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                         LESCARDEN INC.
                         --------------
                         (Registrant)




Date: January 7, 2001    s/Gerard A. Dupuis
                         ------------------
                         Gerard A. Dupuis
                         Chairman of the Board
                         Chief Executive Officer